Merus enters $56M upfront collaboration with Gilead for trispecific antibody programs; potential $1.5B milestones

Merus N.V.

Gilead pays $56M upfront for rights to Merus' Triclonics platform; up to two more programs at $28M each.
Total potential milestones up to ~$1.5B across three programs; tiered royalties mid-single to low double digits.
Gilead purchases 452,527 shares at $55.2454/share (~$25M) in private placement; no transfer for set period.
Merus may elect 50/50 profit-loss share for third program after first IND filing instead of milestones/royalties.
Agreement covers at least two preclinical programs; Gilead has exclusive option per program to license and commercialize.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Merus N.V. entered into Collaboration Agreement with Gilead Sciences, Inc. valued at $56 million (effective 2024-03-05).

Action: entry
Agreement: collaboration
Counterparty: Gilead Sciences, Inc.
Value: $56 million
Effective: 2024-03-05

Exact text from the filing

On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.85

Merus N.V. entered into Share Subscription Agreement with Gilead Sciences, Inc. (effective 2024-03-05).

Action: entry
Agreement: equity purchase
Counterparty: Gilead Sciences, Inc.
Effective: 2024-03-05

Exact text from the filing

On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc. (“Gilead”).

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-060033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.